The Administrative Core will be responsible for the managerial oversight of all Johns Hopkins Prostate SPORE Program activities. In addition, the Core will help facilitate interactions between Johns Hopkins Prostate Cancer SPORE Program Investigators and investigators associated with other Prostate Cancer initiatives. The managerial structure of Johns Hopkins Prostate Cancer SPORE Program, with Its Principal Investigator, Co-Principal Investigator, Executive Committee, Internal Oversight Committee, and External Scientific Advisory Board, has been designed to promote translational research by creating a prostate cancer research culture and transcends academic departments, medical disciplines, and individual research skills, and providing high quality monitoring, evaluation, and oversight of the SPORE portfolio of Research Projects, Core Resources, the Career Development Program, and the Developmental Research Program. The Administrative Core will provide communications, resources, including teleconferences, travel funds, and administrative staffing for all its managerial activities.
Prostate cancer remains the leading cause of cancer of men in the United States. This Core provides for a coordination and facilitation of efforts to bring novel therapeutic approaches to the disease as well as biomarkers that can provide disease signatures.
|Guedes, Liana B; Morais, Carlos L; Almutairi, Fawaz et al. (2016) Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer. Clin Cancer Res 22:4651-63|
|Haffner, Michael C; Weier, Christopher; Xu, Meng Meng et al. (2016) Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization. J Pathol 238:31-41|
|Barakat, David J; Mendonca, Janet; Barberi, Theresa et al. (2016) C/EBPÎ² regulates sensitivity to bortezomib in prostate cancer cells by inducing REDD1 and autophagosome-lysosome fusion. Cancer Lett 375:152-61|
|Murtola, Teemu J; Gurel, Bora; Umbehr, Martin et al. (2016) Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 25:463-9|
|Jackson, Christopher M; Kochel, Christina M; Nirschl, Christopher J et al. (2016) Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination. Clin Cancer Res 22:1161-72|
|Hedayati, Mohammad; Haffner, Michael C; Coulter, Jonathan B et al. (2016) Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation. Clin Cancer Res 22:3310-9|
|Trock, Bruce J; Fedor, Helen; Gurel, Bora et al. (2016) PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance. Mod Pathol 29:764-71|
|Wu, Jianguo; Ivanov, Andrei I; Fisher, Paul B et al. (2016) Polo-like kinase 1 induces epithelial-to-mesenchymal transition and promotes epithelial cell motility by activating CRAF/ERK signaling. Elife 5:|
|Levy, Oren; Brennen, W Nathaniel; Han, Edward et al. (2016) A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. Biomaterials 91:140-50|
|Lotan, Tamara L; Wei, Wei; Morais, Carlos L et al. (2016) PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. Eur Urol Focus 2:180-188|
Showing the most recent 10 out of 691 publications